WP
LYEL icon

Woodline Partners’s Lyell Immunopharma LYEL Stock Holding History

Woodline Partners’s Portfolio LYEL Stock Details LYEL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q3 		– Sell
-98,425
Closed -$870K – 981
2025
Q2 		$870K Buy
+98,425
New +$897K ﹤0.01% 816
2024
Q3 		– Sell
-1,037
Closed -$30.1K – 663
2024
Q2 		$30.1K Hold
1,037
– – ﹤0.01% 545
2024
Q1 		$46.3K Hold
1,037
– – ﹤0.01% 527
2023
Q4 		$40.2K Hold
1,037
– – ﹤0.01% 467
2023
Q3 		$30.5K Hold
1,037
– – ﹤0.01% 580
2023
Q2 		$66K Hold
1,037
– – ﹤0.01% 612
2023
Q1 		$48.9K Hold
1,037
– – ﹤0.01% 615
2022
Q4 		$72K Hold
1,037
– – ﹤0.01% 714
2022
Q3 		$152K Buy
+1,037
New +$140K ﹤0.01% 661
2022
Q2 		– Sell
-10,090
Closed -$1.02M – 847
2022
Q1 		$1.02M Hold
10,090
– – 0.02% 464
2021
Q4 		$1.56M Sell
10,090
-204
-2% -$45.5K 0.02% 448
2021
Q3 		$3.05M Sell
10,294
-14,684
-59% -$4.4M 0.05% 335
2021
Q2 		$8.11M Buy
+24,978
New +$8.19M 0.15% 159

Other funds holding LYEL

AVM
Arch Venture Management Chicago, Illinois $677M AUM 322.07% 1-Year Est. Return
MM
MWG Management Road Town, Tortola, British Virgin Islands $81.3M AUM 2.28% 1-Year Est. Return
FCMI
Foresite Capital Management IV Larkspur, California $237M AUM 107.53% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
OPL
Orland Properties Ltd Road Town, Tortola, British Virgin Islands $267M AUM 5.05% 1-Year Est. Return
DC
Decheng Capital Menlo Park, California $661M AUM 299.97% 1-Year Est. Return
AC
Almitas Capital Santa Monica, California $443M AUM 42.36% 1-Year Est. Return
FCMV
Foresite Capital Management V Larkspur, California $271M AUM 309.87% 1-Year Est. Return
VP
venBio Partners San Francisco, California $281M AUM 261.03% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

Woodline Partners's LYEL Position: Q3 2025 in Review

Woodline Partners sold out of Lyell Immunopharma (LYEL) in Q3 2025, closing a stake of 98,425 shares — an estimated $870K sold.

Woodline Partners first reported a position in LYEL in Q2 2021 and held it in 13 quarters. The position peaked at $8.11M in Q2 2021. 59 funds tracked by Wall St. Rank hold LYEL as of Q3 2025.

  • Woodline Partners reported no remaining Lyell Immunopharma position as of Q3 2025 after selling out during the quarter.
  • Woodline Partners sold 98,425 Lyell Immunopharma shares in Q3 2025, an estimated $870K.
  • Woodline Partners first reported a position in Lyell Immunopharma in Q2 2021 and held it in 13 quarters.
  • Woodline Partners's Lyell Immunopharma position peaked at $8.11M in Q2 2021.
  • 59 funds tracked by Wall St. Rank held Lyell Immunopharma as of Q3 2025.

Based on Woodline Partners's 13F filing for Q3 2025, filed 14 Nov 2025.